Standardized Extract of Valeriana officinalis Improves Overall Sleep Quality in Human Subjects with Sleep Complaints: A Randomized, Double-Blind, Placebo-Controlled, Clinical Study.

The short version

This double-blind randomized trial with 80 adults tested whether valerian — the root extract that has been Europe's traditional sleep herb for centuries — measurably improves sleep when held to modern trial standards. Participants with ongoing sleep complaints took either 200 mg of standardized Valeriana officinalis extract or an identical placebo capsule daily for eight weeks, with neither participants nor researchers knowing who received which. What sets this trial apart is how sleep was measured. Beyond the standard Pittsburgh Sleep Quality Index questionnaire, everyone wore wrist actigraphy devices that objectively track sleep and wake, and half the participants underwent polysomnography — the full laboratory sleep study with brain-wave monitoring that sleep medicine treats as its gold standard. Anxiety, daytime sleepiness, and the feeling of waking refreshed were tracked alongside, with blood work and vital signs monitoring safety throughout. Valerian delivered on nearly every front. Sleep quality scores improved significantly versus placebo by day 14 and stayed better through day 56 (p<0.05). The objective measures agreed: actigraphy showed people falling asleep faster and sleeping longer from day 3 onward, and the laboratory sleep studies confirmed longer total sleep, quicker sleep onset, and better sleep efficiency at eight weeks. Anxiety scores dropped, daytime drowsiness eased, and participants reported waking up more refreshed. No safety signals appeared in any blood test, vital sign, or examination — a meaningful contrast with prescription sleep aids and even melatonin's daytime-drowsiness complaints. This trial offers unusually convergent evidence for valerian in mild sleep complaints: subjective ratings, wrist-worn tracking, and laboratory measurement all pointed the same direction at a modest 200 mg daily dose. The caveats are a moderately sized sample of younger adults with mild symptoms and an eight-week window — the findings do not extend to severe or chronic insomnia.

Key findings

• This double-blind trial randomized 80 adults with sleep complaints to 200 mg standardized valerian extract or placebo daily for eight weeks.
• Sleep improved on every level of measurement: questionnaire scores by day 14, wrist-actigraphy sleep onset and duration from day 3, and gold-standard laboratory polysomnography by day 56.
• Benefits extended beyond sleep - anxiety scores fell, daytime drowsiness eased, and participants woke feeling more refreshed.
• Safety monitoring including blood work found no concerns across eight weeks, distinguishing valerian from the side-effect profiles of common sleep medications.
• The evidence applies most directly to younger adults with mild insomnia symptoms; severe or chronic insomnia still warrants clinical care.

Common questions